This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics and explore the pharmacodynamics of ascending single doses of BAY1834845 using a placebo controlled, randomized, single center design.
- Healthy male subject - Age: 18 to 50 years (inclusive) at the first screening visit - Body mass index (BMI) : 18.5 ≤ BMI ≤ 30 kg/m²
- Clinically relevant findings in the physical examination - Relevant diseases within the last 4 weeks prior to the first study drug administration - Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal - Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks before first study drug administration
CRS Clinical Research Services Berlin GmbH
Berlin, Germany, 13353
E-mail: [email protected]
Phone: (+)1-888-84 22937
Randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics and to explore pharmacodynamics of increasing single oral doses of BAY1834845 including relative bioavailability of a liquid versus a solid dosage in healthy male volunteers